Skip to main content

Non-cognitive benefits of galantamine (Reminyl®) treatment in vascular dementia

Buy Article:

$51.00 plus tax (Refund Policy)


Kurz A. Non-cognitive benefits of galantamine (Reminyl®) treatment in vascular dementia.

Acta Neurol Scand 2002: 106 (Suppl. 178): 19–24. © Blackwell Munksgaard 2002.

Vascular dementia (VaD) is a condition that involves deterioration in cognitive and non-cognitive areas. Although cognitive impairment is the defining symptom evaluated during clinical trials, changes in non-cognitive areas such as behavior, global functioning and activities of daily living are assessed because they assist in determining quality of life and overall well-being. Therapy has focused traditionally on preventing and controlling risk factors, as no approved treatments are currently available for these patients. Acetylcholinesterase inhibitors (AChEIs), the treatment of choice in patients with Alzheimer's disease (AD), are a potential treatment option for patients with VaD. Galantamine, an AChEI with nicotinic receptor modulation, has demonstrated clinically relevant benefits (cognition, global functioning, functional ability, behavior) in patients with either AD with cerebrovascular disease (AD with CVD) or probable VaD in a 6-month, randomized, double-blind, placebo-controlled study.

Keywords: acetylcholinesterase inhibitors; galantamine; non-cognitive symptoms; treatment; vascular dementia

Document Type: Research Article


Affiliations: Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany

Publication date: December 1, 2002


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more